Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes to the stem region, and methods of making and using both.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
September 15, 2020
Assignees:
Dana-Farber Cancer Institute, Inc., Burnham Institute for Medical Research
Inventors:
Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.
Type:
Grant
Filed:
August 12, 2013
Date of Patent:
April 24, 2018
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Inventors:
Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
Abstract: Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell.
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
April 4, 2017
Assignees:
Burnham Institute for Medical Research, Hamamatsu University School of Medicine
Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
Abstract: We have developed a reduced Drosophila heart preparation in which dissection of the fly heart removes nervous system input and reveals its inherent myogenic activity, which can be preserved for several hours. High speed image capture combined with computer-based analytical packages allows us to generate the equivalent of M-mode traces obtained from ultrasounds of human hearts.
Type:
Grant
Filed:
August 20, 2009
Date of Patent:
November 17, 2015
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently selected from the group consisting of H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, and NHSO2X, wherein X is selected from the group consisting of an alkyl, a substituted alkyl, an aryl, a substituted aryl, an alkylaryl, and a heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.
Type:
Application
Filed:
August 12, 2013
Publication date:
January 9, 2014
Applicants:
BURNHAM INSTITUTE FOR MEDICAL RESEARCH, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
Abstract: Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.
Type:
Grant
Filed:
August 29, 2003
Date of Patent:
June 11, 2013
Assignee:
The Burnham Institute
Inventors:
Elena B. Pasquale, Mitchell Koolpe, Keith K. Murai
Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.
Type:
Grant
Filed:
February 2, 2009
Date of Patent:
September 25, 2012
Assignee:
The Burnham Institute
Inventors:
John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
Type:
Grant
Filed:
October 30, 2008
Date of Patent:
September 4, 2012
Assignees:
Burnham Institute for Medical Research, The Texas A&M University System
Inventors:
Jeffrey W. Smith, Daniel Romo, Gil Ma, Manuel Zancanella
Abstract: The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such and in combination with conventional therapies, such as surgery and radiation, and anti-angiogenic therapies, and as a tool in diagnosis of, e.g., invasive brain cancer or metastatic brain lesions.
Type:
Grant
Filed:
May 8, 2009
Date of Patent:
May 29, 2012
Assignees:
Burnham Institute for Medical Research, The Regents of the University of California, UCSF
Inventors:
Pirjo Laakkonen, Erkki Ruoslahti, Gabriele Bergers
Abstract: Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.
Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.
Type:
Application
Filed:
August 25, 2009
Publication date:
May 24, 2012
Applicants:
Burnham Institute for Medical Research, Dana-Farber Cancer Institute, Inc.
Inventors:
Wayne Marasco, Jianhua Sui, Robert C. Liddington
Abstract: This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders.
Abstract: The present invention provides screening methods for the detection of agents that affect various aspects of ?-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect ?-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
Type:
Grant
Filed:
November 7, 2008
Date of Patent:
May 1, 2012
Assignees:
Burnham Institute for Medical Research, The Regents of the University of California
Inventors:
Fred Levine, Pamela Itkin-Ansari, Mark Mercola